Cohort study: Piperacillin/tazobactam linked to increased risk of acute kidney injury when compared to cefepime or meropenem

Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin – Clinical Infectious Diseases

Commentary on Twitter

NEW ?? #CID @IDSAInfo
Risk of AKI & CDI with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin #IDTwitter @danlivorsi
TZP ⬆️ AKI risk, which was exacerbated by concurrent vancomycin.
FEP&MER ⬆️CDI risk relative to TZP. https://t.co/0pIurl7A7w pic.twitter.com/ZjjvN2rkWP

— Antibiotic Steward? Bassam Ghanem (@ABsteward) December 31, 2020